Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
View Patent ↗A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of eicosapentanoic acid ethyl ester (EPA), of docosahexaenoic acid ethyl ester (DHA), or of a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), especially a mixture of EPA and DHA in an EPA/DHA ratio in the range from about 0.9 to about 1.5 at a dosage of from about 0.7 g to about 6 g per day.
1. A method for treating or inhibiting depression in a patient with coronary heart disease or coronary artery disease, said method consisting of orally administering to said patient a therapeutically effective dosage of from 0.7 g to 6 g per day of an essential fatty acid composition comprising a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) in an EPA/DHA ratio in the range from 0.9 to 1.5.
2. A method according to claim 1 , wherein said composition contains more than 25% by weight of the mixture of EPA and DHA.
3. A method according to claim 1 , wherein said composition contains from 30 to 100% by weight of the mixture of EPA and DHA.
4. A method according to claim 3 , wherein said composition contains 85% by weight of the mixture of EPA and DHA.